Marksans Pharma Receives USFDA Approval For Benzonatate Capsules

Marksans Pharma Ltd, a leading pharmaceutical company, has secured USFDA approval for Benzonatate Capsules USP. This milestone reflects the company’s focus on expanding its presence in regulated markets and diversifying its product offerings.

Approval Details
The approval covers Benzonatate Capsules USP in 100 mg and 200 mg strengths, used for the symptomatic relief of cough. Marksans Pharma will manufacture the product at its USFDA-approved facility, ensuring compliance with global quality standards.

Strategic Importance
This approval enhances Marksans Pharma’s portfolio in the US, one of the largest pharmaceutical markets globally. It also reinforces the company’s strategy of strengthening its generics pipeline and expanding its therapeutic reach.

Future Outlook
Analysts expect the approval to contribute positively to Marksans Pharma’s revenue growth. The company’s continued focus on regulatory approvals and product launches positions it well for sustained expansion in international markets.

Key Highlights

• Marksans Pharma receives USFDA approval for Benzonatate Capsules
• Approval covers 100 mg and 200 mg strengths
• Product indicated for symptomatic relief of cough
• Strengthens company’s US generics portfolio
• Supports growth in regulated international markets

Sources: Economic Times, Business Standard, Marksans Pharma release